about
A structured review of health utility measures and elicitation in advanced/metastatic breast cancerPertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancerTrastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Estimating utility weights and quality-adjusted life year loss for colorectal cancer-related health states in KoreaPopulation preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study.A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death.Patient preferences for side effects associated with cervical cancer treatmentCost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer.Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.Willingness to pay to avoid metastatic breast cancer treatment side effects: results from a conjoint analysis.Impact of obesity and knee osteoarthritis on morbidity and mortality in older AmericansUsing quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trialEverolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness AnalysisCost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands.Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review.Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancerPopulation preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United KingdomCost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer.Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients.Health state utilities for non small cell lung cancer.Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in CanadaCost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada.Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective.Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor-and HER2-Positive Metastatic Breast CancerCost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer.Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin LymphomaHealth-state utility values in breast cancer.Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique.A systematic review of utility values for chemotherapy-related adverse events.Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.Pharmacoeconomic analysis for pemetrexed as a maintenance therapy for NSCLC patients with patient assistance program in China.Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
P2860
Q28067255-D20CB258-1631-416D-A7FC-BE60A2EABC8EQ28246333-256939E3-78DA-49AB-A0AE-CF943F5190A0Q33430119-859E0B92-6D83-494E-A7D1-60901CA76865Q33912097-E5D08B63-229A-4DE2-ACD6-6CA5670771B7Q33934317-44018E4F-8A59-4DF9-9CC7-85EE107D285EQ34029999-B26354C8-F8DA-4D37-8E33-D7A1F07D7540Q34235050-7692C860-CD01-4353-AB5E-3C1217D84607Q34871388-9BBD0B06-56BB-4325-83C6-1439CB336BE7Q35053793-576813A7-97D0-4B15-8433-94629E439DB1Q35584343-32137A40-4BD9-4BA9-AD64-436D0C523977Q35661600-4767FE68-35FE-4532-AC4E-8E99DB1D63BBQ35678474-23168799-B4D8-4F64-8B1A-82C53E69A9B0Q35705716-7FA86238-D665-466C-BD54-7688CBBF3628Q35736115-7E9CA7DA-BF0C-4E07-BC18-FC3012F0BA17Q35754399-CA923B39-0C67-4D02-ABE2-09989B5EF7A3Q35773340-85C1D086-B01F-43B0-BDAB-3933DCBF8F62Q36123151-7B2B10C6-C541-4A5B-978D-AF92202A22F4Q36135938-5C760CFB-154A-4544-BEB1-693F1551C3BEQ36265153-8307B093-AE73-4D5A-9A5A-0CAFE9E8883BQ36287149-E29D8E02-D8EE-4C7F-960E-BF199B788C72Q36699064-29180336-EB77-48D8-BF15-C452408A8934Q36848631-7C73835E-D156-47C2-B72C-60657CF80D63Q36963976-9DCD75C6-5FF2-484C-BA97-C0EFB9A33C8BQ37152908-B500A27D-C600-4CCB-A474-8470F0910A63Q37247986-3E08A64C-F7AD-461B-B00B-532724E529CEQ37269696-18C62D32-A2AC-4F37-B987-585D1B5D9D41Q37355937-C39F440A-1115-481B-8AE9-D04745A96CD8Q37573906-70B2907F-2F7A-4719-AF23-80716E59E44DQ37577682-17B4FB2A-33B3-473B-A52B-31180FE59CF3Q37710149-FA4556FB-65AB-41A2-8349-E3587829791DQ37800481-77AD33A0-F4A7-48A0-9965-5C950449A380Q38084203-F6380259-DB2B-495F-9B5C-C5EB340B9E94Q38093053-76070B8E-E8DF-4DE3-803E-1467322DA5A5Q38212030-85E3F996-2797-49D6-9B62-B4C31A0A9D8CQ38248466-405DC3CE-6F25-4BFB-9C4B-30EDB7B9E985Q38603487-FECCE167-BAAA-4E8F-A5B5-82A1AEDE2A47Q38608747-661F3EDC-2D95-4FE0-BB41-B0EE9DF3C4A8Q38645144-D5F4C39C-7B72-4D29-8E6A-261EA856835AQ38680945-537A0C88-F32C-4578-AB67-F4D23EDCD7E4Q38702281-4E84D4B0-69EA-4EB1-B3D4-979FB36BEA5D
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Health state utilities for metastatic breast cancer.
@ast
Health state utilities for metastatic breast cancer.
@en
type
label
Health state utilities for metastatic breast cancer.
@ast
Health state utilities for metastatic breast cancer.
@en
prefLabel
Health state utilities for metastatic breast cancer.
@ast
Health state utilities for metastatic breast cancer.
@en
P2093
P2860
P356
P1476
Health state utilities for metastatic breast cancer.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603326
P407
P577
2006-09-01T00:00:00Z
P5875
P6179
1018621148